BriaCell Therapeutics Files S-1 for Potential Offering
Ticker: BCTXZ · Form: S-1 · Filed: Apr 22, 2025 · CIK: 1610820
Sentiment: neutral
Topics: s-1, offering, biotech
TL;DR
BriaCell Therapeutics just filed an S-1, looks like they're gearing up for a stock offering. Keep an eye on this one.
AI Summary
BriaCell Therapeutics Corp. filed an S-1 registration statement on April 22, 2025, for an unspecified offering. The company, formerly known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and headquartered in West Vancouver, BC. The filing indicates a potential public offering of securities, though specific details on the amount or type of securities are not yet disclosed in this initial filing.
Why It Matters
This S-1 filing signals BriaCell Therapeutics' intention to raise capital through a public offering, which could fund its ongoing research and development in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, BriaCell Therapeutics faces inherent risks associated with drug development and regulatory approvals, making its S-1 filing indicative of potential volatility.
Key Numbers
- 333-286670 — SEC File Number (Identifies the specific SEC registration)
- 0001610820 — Central Index Key (Unique identifier for the company in SEC filings)
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- April 22, 2025 (date) — Filing date
- June 13, 2014 (date) — Date of name change
- Dr. William V. Williams (person) — Chief Executive Officer
- Gregory Sichenzia, Esq. (person) — Legal counsel
- Avital Perlman, Esq. (person) — Legal counsel
FAQ
What is the purpose of this S-1 filing for BriaCell Therapeutics Corp.?
The S-1 filing is a registration statement filed with the SEC to register securities for a potential public offering, though the specific details of the offering are not yet disclosed.
When was BriaCell Therapeutics Corp. formerly known by another name?
BriaCell Therapeutics Corp. was formerly known as Ansell Capital Corp. until June 13, 2014.
Who is the Chief Executive Officer of BriaCell Therapeutics Corp.?
Dr. William V. Williams is the Chief Executive Officer of BriaCell Therapeutics Corp.
What is the principal executive office address for BriaCell Therapeutics Corp.?
The principal executive office address is Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1.
What is the SIC code for BriaCell Therapeutics Corp.?
The Standard Industrial Classification (SIC) code for BriaCell Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on April 22, 2025 by Dr. William V. Williams regarding BriaCell Therapeutics Corp. (BCTXZ).